Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 107

1.

Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial.

Carbonell-Estrany X, Simões EA, Dagan R, Hall CB, Harris B, Hultquist M, Connor EM, Losonsky GA; Motavizumab Study Group.

Pediatrics. 2010 Jan;125(1):e35-51. doi: 10.1542/peds.2008-1036. Epub 2009 Dec 14.

PMID:
20008423
[PubMed - indexed for MEDLINE]
Free Article
2.

Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants.

Pedraz C, Carbonell-Estrany X, Figueras-Aloy J, Quero J; IRIS Study Group.

Pediatr Infect Dis J. 2003 Sep;22(9):823-7.

PMID:
14506376
[PubMed - indexed for MEDLINE]
3.

Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing.

Simoes EA, Groothuis JR, Carbonell-Estrany X, Rieger CH, Mitchell I, Fredrick LM, Kimpen JL; Palivizumab Long-Term Respiratory Outcomes Study Group.

J Pediatr. 2007 Jul;151(1):34-42, 42.e1.

PMID:
17586188
[PubMed - indexed for MEDLINE]
5.

Impact of palivizumab prophylaxis on respiratory syncytial virus hospitalizations in high risk Alaska Native infants.

Singleton R, Dooley L, Bruden D, Raelson S, Butler JC.

Pediatr Infect Dis J. 2003 Jun;22(6):540-5.

PMID:
12799511
[PubMed - indexed for MEDLINE]
6.

Palivizumab prophylaxis and hospitalization for respiratory syncytial virus disease in the Stockholm infant population, 1999 through 2002.

Henckel E, Luthander J, Berggren E, Kapadia H, Naver L, Norman M, Bennet R, Eriksson M.

Pediatr Infect Dis J. 2004 Jan;23(1):27-31.

PMID:
14743042
[PubMed - indexed for MEDLINE]
7.

A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season.

Fernández P, Trenholme A, Abarca K, Griffin MP, Hultquist M, Harris B, Losonsky GA; Motavizumab Study Group.

BMC Pediatr. 2010 Jun 3;10:38. doi: 10.1186/1471-2431-10-38.

PMID:
20525274
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Risk of severe respiratory syncytial virus disease, identification of high risk infants and recommendations for prophylaxis with palivizumab.

Meissner HC, Rennels MB, Pickering LK, Hall CB.

Pediatr Infect Dis J. 2004 Mar;23(3):284-5. No abstract available.

PMID:
15014320
[PubMed - indexed for MEDLINE]
9.

Nationwide survey of palivizumab for respiratory syncytial virus prevention in Japanese children with congenital heart disease.

Saji T, Nakazawa M, Harada K.

Pediatr Infect Dis J. 2008 Dec;27(12):1108-9. doi: 10.1097/INF.0b013e3181801d76.

PMID:
18978515
[PubMed - indexed for MEDLINE]
10.

Safety, tolerability, pharmacokinetics, and immunogenicity of motavizumab, a humanized, enhanced-potency monoclonal antibody for the prevention of respiratory syncytial virus infection in at-risk children.

Abarca K, Jung E, Fernández P, Zhao L, Harris B, Connor EM, Losonsky GA; Motavizumab Study Group.

Pediatr Infect Dis J. 2009 Apr;28(4):267-72. doi: 10.1097/INF.0b013e31818ffd03.

PMID:
19258920
[PubMed - indexed for MEDLINE]
11.

[Palivizumab--a monoclonal antibody for passive immunoprophylaxis of respiratory syncytial virus infections].

Scholz H.

Z Geburtshilfe Neonatol. 2000 May-Jun;204(3):120-2. German.

PMID:
10909169
[PubMed - indexed for MEDLINE]
12.
13.

Palivizumab: a review of its use as prophylaxis for serious respiratory syncytial virus infection.

Fenton C, Scott LJ, Plosker GL.

Paediatr Drugs. 2004;6(3):177-97.

PMID:
15170364
[PubMed - indexed for MEDLINE]
14.

Improved outcomes with home-based administration of palivizumab: results from the 2000-2004 Palivizumab Outcomes Registry.

Frogel M, Nerwen C, Boron M, Cohen A, VanVeldhuisen P, Harrington M, Groothuis J; Palivizumab Outcomes Registry Group.

Pediatr Infect Dis J. 2008 Oct;27(10):870-3. doi: 10.1097/INF.0b013e318174e0c4.

PMID:
18776822
[PubMed - indexed for MEDLINE]
15.

Guidelines for palivizumab prophylaxis: are they based on infant's risk of hospitalization for respiratory syncytial viral disease?

Elhassan NO, Stevens TP, Sorbero ME, Dick AW, Guillet R, Hall CB.

Pediatr Infect Dis J. 2003 Nov;22(11):939-43.

PMID:
14614363
[PubMed - indexed for MEDLINE]
16.

Incidence of respiratory syncytial virus-related hospitalizations in high-risk children: follow-up of a national cohort of infants treated with Palivizumab as RSV prophylaxis.

Lacaze-Masmonteil T, Rozé JC, Fauroux B; French Pediatricians' Group of Sunagis Patients' Name-Based Programs.

Pediatr Pulmonol. 2002 Sep;34(3):181-8.

PMID:
12203846
[PubMed - indexed for MEDLINE]
17.

Prophylaxis in RSV infection (Palivizumab)--is it worthwhile?

Hashmi NA, Cosgrove JF, MacMahon P.

Ir Med J. 2000 Dec;93(9):284.

PMID:
11209917
[PubMed - indexed for MEDLINE]
18.

Factors impacting compliance with palivizumab prophylaxis.

Pignotti MS, Indolfi G, Donzelli G.

Pediatr Infect Dis J. 2004 Feb;23(2):186-7. No abstract available.

PMID:
14872196
[PubMed - indexed for MEDLINE]
19.

Regional impact of prophylaxis with the monoclonal antibody palivizumab on hospitalisations for respiratory syncytial virus in infants.

Duppenthaler A, Gorgievski-Hrisoho M, Aebi C.

Swiss Med Wkly. 2001 Mar 24;131(11-12):146-51.

PMID:
11416887
[PubMed - indexed for MEDLINE]
Free Article
20.

Respiratory syncytial virus disease: update on treatment and prevention.

Krilov LR.

Expert Rev Anti Infect Ther. 2011 Jan;9(1):27-32. doi: 10.1586/eri.10.140. Review.

PMID:
21171875
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk